Low-grade Oncocytic Fumarate Hydratase-deficient Renal Cell Carcinoma in a Patient with Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome: A Case Report
This case report describes a rare instance of low-grade, organ-confined oncocytic fumarate hydratase-deficient renal cell carcinoma in a patient with hereditary leiomyomatosis and renal cell carcinoma syndrome, highlighting that favorable outcomes can occur despite the typically aggressive nature of this tumor type and underscoring that germline genotype alone does not dictate prognosis.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Most people think of cancer as a single, relentless force, but in the world of medicine, tumors are often as diverse as the people who carry them. Some grow slowly, while others race through the body with terrifying speed. A specific type of kidney cancer, known as fumarate hydratase-deficient renal cell carcinoma, has long been feared for its aggression. This disease occurs when a crucial enzyme in the body's energy factory, called fumarate hydratase, stops working. Without this enzyme, harmful substances build up inside cells, driving them to become cancerous. This condition is frequently linked to a hereditary syndrome called HLRCC, which runs in families and predisposes individuals to benign growths in the skin and uterus, as well as these dangerous kidney tumors. Because the disease is so often aggressive, doctors have generally assumed that any kidney cancer with this specific genetic flaw would be high-grade and deadly, requiring immediate and drastic treatment.
A recent case report from a team of Japanese researchers challenges this assumption by documenting a rare exception. The story begins with a woman in her seventies who noticed a swelling on the left side of her neck. When doctors scanned her body to investigate the lump, they unexpectedly discovered multiple small tumors in both of her kidneys. While the neck mass turned out to be a harmless thyroid nodule, the kidney findings were significant. The patient had a family history of uterine fibroids stretching back four generations, a pattern that strongly hinted at the hereditary syndrome. Following a minimally invasive surgery to remove the tumors from her left kidney, pathologists examined the tissue under a microscope. Instead of the chaotic, high-grade cells typical of this disease, they found a tumor that was surprisingly orderly. The cells looked like low-grade oncocytic tumors, a type that usually grows slowly and stays contained within the kidney.
To confirm what they were seeing, the medical team ran a series of specialized tests on the tumor tissue. They looked for the presence of the fumarate hydratase enzyme and found it was missing, while a marker that accumulates when the enzyme is absent was clearly present. This confirmed the diagnosis of fumarate hydratase-deficient renal cell carcinoma. However, the tumor did not behave like the aggressive versions seen in other patients. It was small, confined entirely to the kidney, and showed no signs of spreading or the destructive changes often associated with high-grade cancers. The researchers then tested the patient's blood and found a specific genetic change, a missense variant in the FH gene, which confirmed she had the hereditary syndrome. This specific genetic change had been seen before in other patients, but in those cases, it was linked to very aggressive, fast-growing tumors.
The most striking aspect of this discovery is that the same genetic error that caused a deadly tumor in one person caused a slow-growing, manageable one in another. This finding suggests that a person's genetic code alone does not dictate how a cancer will behave. While the inherited mutation sets the stage, other factors within the tumor itself determine whether it will be a gentle growth or a fierce invader. The patient in this report has remained free of recurrence or spread, and her remaining small tumor in the other kidney is being watched closely rather than removed. This case serves as a vital reminder that even within a disease known for its severity, there is room for variation. It underscores the importance of treating every patient individually, using genetic testing to guide care while recognizing that the presence of a dangerous gene does not automatically mean a poor outcome.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.